Clinical Trial

DT-168 in Keratoplasty Patients With Fuchs Endothelial Corneal Dystrophy

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the pharmacodynamics, safety, and tolerability of DT-168 Ophthalmic Solution in pre-keratoplasty patients with Fuchs endothelial corneal dystrophy.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-06-09; most recent amendment 2025-12-24.
Status change: Not Yet Recruiting → Recruiting 2025-06-17
Trial Details
NCT Number NCT07024693
Lead Sponsor Design Therapeutics, Inc.
Conditions Fuchs Endothelial Corneal Dystrophy, Fuchs
Enrollment 28 participants
Start Date 2025-07-30
Primary Completion 2026-09 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2025-12-29